pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Immuno-Oncology

Jan 19, 2023

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

Jan 5, 2023

Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million

Dec 20, 2022

Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology

Dec 8, 2022

Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts

Nov 17, 2022

Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

Nov 1, 2022

Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets

Oct 18, 2022

Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board

Oct 17, 2022

Ankyra Therapeutics Appoints Joseph J. Elassal, M.D., MBA, a Veteran Immuno-oncology Expert, as Chief Medical Officer

Aug 1, 2022

Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company

Aug 1, 2022

Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic

Jul 26, 2022

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug USA - English USA - English

Jul 26, 2022

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

Jul 11, 2022

Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug USA - English USA - English

Jul 11, 2022

Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug

Jun 28, 2022

Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck for M1069 Clinical Development in Immuno-Oncology

Jun 13, 2022

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

Jun 10, 2022

Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology

Jun 2, 2022

Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis LW-02 Column is Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer

Jun 1, 2022

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

May 18, 2022

Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022

May 10, 2022

Domain Therapeutics Raises $42m Series A Financing

Apr 13, 2022

OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting

Apr 8, 2022

Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting

Mar 31, 2022

Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target

Mar 22, 2022

Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics

Mar 18, 2022

Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

Mar 16, 2022

MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies

Mar 10, 2022

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Feb 28, 2022

ICHNOS SCIENCES ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD TO INFORM RESEARCH AND DEVELOPMENT STRATEGY IN IMMUNO-ONCOLOGY

Feb 24, 2022

GI Innovation Signs MoU With Cellkey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology

Feb 15, 2022

Grey Wolf Therapeutics Announces Formation of Clinical Advisory Board in Anticipation of Advancing First-in-Class Immuno-Oncology Approach into the Clinic

Jan 5, 2022

Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific Officer

Dec 20, 2021

Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

Dec 17, 2021

Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021

Dec 8, 2021

OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads

Nov 21, 2021

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China USA - English España - español USA - English

Nov 12, 2021

Ankyra Therapeutics Announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. as Chief Medical Officer

Nov 12, 2021

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

Nov 2, 2021

Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform

Nov 1, 2021

7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines

Oct 27, 2021

Biomica and Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug USA - English USA - English

Oct 27, 2021

Biomica and Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug

Oct 25, 2021

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

Oct 14, 2021

MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies

Oct 7, 2021

Kineta Presents Preclinical Data on Its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy

Oct 4, 2021

Humedix Closes Strategic Investment in US-based Kineta to boost CMO business

Aug 18, 2021

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

Jul 27, 2021

AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases

Jul 20, 2021

MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies

Jul 15, 2021

Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology RandD USA - English USA - English

Jun 23, 2021

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

Jun 23, 2021

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

Jun 1, 2021

Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program

May 19, 2021

MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies

May 11, 2021

Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum

Apr 26, 2021

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Apr 9, 2021

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Apr 7, 2021

PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration

Mar 18, 2021

Boundless Bio Appoints Shailaja Kasibhatla, Ph.D., as Vice President, Discovery and Translational Development

Mar 10, 2021

Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets

Feb 24, 2021

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

Feb 24, 2021

Metagenomi Announces the Addition of Leading Immuno-oncology Clinical Research Experts to its Scientific Advisory Board

Feb 17, 2021

Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology

Jan 13, 2021

KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies

Jan 11, 2021

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Jan 8, 2021

ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer USA - English USA - English USA - English España - español España - español Deutschland - Deutsch Deutschland - Deutsch France - Français France - Français

Jan 8, 2021

ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer USA - English Israel - English USA - español USA - Deutsch USA - Français

Jan 7, 2021

Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic

Dec 18, 2020

Janux Therapeutics Announces Collaboration with Merck to Develop Novel Drug Candidates for Immuno-Oncology using T Cell Engager (TRACTr) Technology

Dec 18, 2020

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

Oct 13, 2020

Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program USA - English USA - English

Oct 13, 2020

Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer

Sep 17, 2020

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

Sep 8, 2020

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program USA - English USA - English

Aug 24, 2020

Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Jul 16, 2020

F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration

Jul 16, 2020

Oncorus Initiates First-in-Human Phase 1 Study of ONCR-177 for the Treatment of Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors

Jun 16, 2020

Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team

Jun 15, 2020

7 Hills Pharma Highlights Cell Adhesion as Key to Improving Effectiveness of Covid-19 Vaccines and Immuno-Oncology Drugs At BIO Digital 2020 Online Conference

Jun 11, 2020

Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing

Jun 11, 2020

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

May 14, 2020

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

May 7, 2020

Cybrexa Therapeutics to Present at BIO Digital and Sachs 6th Annual Digital Immuno-Oncology Innovation Forum

May 5, 2020

Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology Programs

Apr 21, 2020

Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board

Apr 14, 2020

Applied BioMath Announces Collaboration with OncoMyx Therapeutics for Systems Pharmacology Modeling in Immuno-Oncology

Mar 24, 2020

Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline

Mar 9, 2020

NKMax America to Present at Immuno-Oncology Summit Europe 2020

Mar 3, 2020

EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance

Feb 27, 2020

Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board

Feb 25, 2020

KAHR Medical Raises $18 Million in Private Funding Round USA - English USA - English USA - English

Feb 20, 2020

Eureka Therapeutics to Present at 6th Annual Immuno-Oncology 360° Conference

Feb 13, 2020

Calidi Biotherapeutics Presents Data at The 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Feb 3, 2020

Calidi Biotherapeutics Announces Abstract Acceptance for Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 27, 2020

Immunomic Therapeutics Sr. Scientist Dr. Pratima Sinha to Present at SITC-ASCO Clinical Immuno-Oncology Symposium 2020

Jan 22, 2020

Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Jan 13, 2020

Pear Therapeutics Announces Collaboration with Apricity Health to Advance Prescription Digital Therapeutics to be Prescribed in Combination with Immuno-oncology Therapy

Jan 13, 2020

Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 and BMC127 for its Immuno-Oncology Program USA - English USA - English

Jan 10, 2020

Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy

Jan 8, 2020

Lava Therapeutics Appoints Immuno-Oncology Experts James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., to Advisory Board

Dec 12, 2019

Bioncotech Therapeutics Phase I BO-112 Data Presented at ESMO Immuno-Oncology Congress 2019

Dec 10, 2019

Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo (Nivolumab)

Dec 3, 2019

KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

Nov 12, 2019

Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program USA - English USA - English

Nov 4, 2019

Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

Oct 28, 2019

KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine

Oct 22, 2019

Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory Board

Sep 28, 2019

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor

Sep 28, 2019

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor

Sep 19, 2019

Celsius Therapeutics Signs Multiple Agreements with Academic Institutions to Access Samples for the Identification of Novel Targets in Immune Checkpoint Therapy Resistance

Sep 17, 2019

Navrogen Announces The Closing Of $3.2M Funding To Support Its Humoral Immuno-Oncology Platform Discovery Technologies And Preclinical Pipeline

Jul 17, 2019

Pyxis Oncology Founded by Longwood Fund with Financing Led by Bayer

Jun 25, 2019

Vycellix Announces Formation of Scientific Advisory Board

Jun 17, 2019

Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471

May 28, 2019

Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

May 24, 2019

Immunomic Therapeutics to Participate at Sach’s 5th Annual Immuno-oncology BD&L and Investment Forum

May 24, 2019

Immunomic Therapeutics to Participate at Sach’s 5th Annual Immuno-oncology BDandL and Investment Forum

May 3, 2019

Dr. Thomas Ichim Appointed President and Chief Executive Officer of Batu Biologics Inc.

Apr 16, 2019

Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program USA - English USA - English

Apr 11, 2019

Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

Mar 28, 2019

Yisheng Biopharma Announces Research Presentation of Immuno-Oncology Product at AACR Annual Meeting 2019

Mar 26, 2019

Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target

Mar 1, 2019

AIVITA Biomedical to Present Cancer Vaccine Data at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Feb 12, 2019

Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

Feb 11, 2019

Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies to increase tumour visibility

Jan 18, 2019

Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

Jan 15, 2019

Immunocore Names David Berman as Head of RandD

Jan 10, 2019

GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology

Jan 7, 2019

Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

Jan 3, 2019

Mavupharma Selects First Immuno-Oncology Clinical Candidate MAVU-104, an Oral STING Pathway Enhancer

Dec 17, 2018

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

Dec 14, 2018

Astellas Acquires Potenza Therapeutics

Dec 4, 2018

TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs

Nov 9, 2018

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

Nov 6, 2018

Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate

Oct 31, 2018

Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

Sep 28, 2018

KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD-1 Resistant Solid Tumors

Sep 24, 2018

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog

Sep 10, 2018

Immunomic Therapeutics Appoints Recognized Immuno-Oncology Expert, Dr. Richard Ambinder, to its Scientific Advisory Board

Sep 5, 2018

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Aug 29, 2018

Immunomic Therapeutics CEO to Present at Immuno-Oncology Summit

Aug 23, 2018

Invitation From Dr James Legg, VP R&D at Crescendo Biologics, Chair of This Year's Immuno-Oncology Conference

Aug 8, 2018

Apexigen Raises $73 Million In Series B And Series C Financings

Jul 24, 2018

F-star Announces the Achievement of a Clinical Milestone in its Immuno-Oncology Collaboration with Merck

Jun 26, 2018

7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program

Jun 11, 2018

Nobel Prize Winning Immunologist Joins Batu Biologics in Quest to “Starve the Tumor”

Jun 7, 2018

Atreca to Present Immuno-Oncology Research Findings at 2018 World Preclinical Congress

May 31, 2018

Northern Biologics’ MSC-1 Enters the Clinic

May 31, 2018

eTheRNA to Present at Sachs' 4th Annual Immuno-Oncology BDandL and Investment Forum

May 30, 2018

Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials

May 30, 2018

Triumvira Immunologics to Participate in Two Upcoming Conferences: Sachs Immuno-Oncology BDandL and Investment Forum and 2018 BIO International Convention

May 21, 2018

F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody

May 16, 2018

Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model

Apr 30, 2018

GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit

Apr 23, 2018

CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy

Apr 5, 2018

Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models

Mar 22, 2018

Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-Mediated Diseases

Mar 22, 2018

Kineta Immuno-Oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference

Mar 22, 2018

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

Mar 19, 2018

American Gene Technologies Gains Additional Immuno-Oncology Patent

Mar 15, 2018

IDEAYA Biosciences Raises $94 Million Crossover Series B Financing

Feb 13, 2018

Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics and Biosimilars Congress Europe (March 2018)

Jan 22, 2018

Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference

Jan 8, 2018

APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi

Jan 8, 2018

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi

Jan 5, 2018

Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs

Jan 4, 2018

Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab

Dec 19, 2017

GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets

Dec 12, 2017

American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer through Activation of Gamma Delta T Cells

Nov 29, 2017

NeoPhore Scientific Founders Publish Breakthrough Immuno-oncology Discoveries in Nature

Nov 15, 2017

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company

Nov 8, 2017

Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth

Nov 3, 2017

Opening Ceremony of CStone Pharmaceuticals' Suzhou Translational Medicine Research Center and an associated Immuno-Oncology Forum was Successfully Held in Suzhou

Nov 1, 2017

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells

Oct 19, 2017

Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a

Oct 18, 2017

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Oct 12, 2017

IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer

Oct 4, 2017

Palleon Pharmaceuticals Raises $47.6 Million to Develop Glycoimmune Checkpoint Inhibitors, a New Class of Medicines Designed to Overcome Resistance to First-Generation Immuno-Oncology Drugs

Oct 3, 2017

Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer

Sep 21, 2017

FLX Bio Selects Immuno-Oncology Clinical Candidate

Sep 6, 2017

Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology

Aug 22, 2017

Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody

Jul 25, 2017

Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration

Jun 20, 2017

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

Jun 14, 2017

Atreca to Participate in Immuno-Oncology Panel at the 2017 BIO International Convention

Jun 4, 2017

Merck KGaA, Darmstadt, Germany, Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody

May 31, 2017

FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board

May 1, 2017

Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors

Mar 31, 2017

CORRECTING and REPLACING -- FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4

Mar 31, 2017

FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4

Mar 7, 2017

ImmunoMet Therapeutics Raises $5.0 million in a Series B Financing

Feb 24, 2017

Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy

Feb 23, 2017

MabSpace Biosciences to Present Preclinical Data on Second Generation PD-L1 Antibody with pH-Dependent Antigen Binding Property at Upcoming Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium

Jan 23, 2017

Merck KGaA, Darmstadt, Germany, Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology

Jan 6, 2017

Atreca, Inc. to Participate in Immuno-Oncology Panel at 9th Annual Biotech Showcase

Jan 6, 2017

Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic

Jan 4, 2017

Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors

Jan 4, 2017

Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics

Dec 13, 2016

Atreca and A*STAR’s Genome Institute of Singapore Establish Joint Laboratory for Immuno-Oncology

Dec 7, 2016

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal's CriPec nanotech platform

Dec 1, 2016

Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis Platform

Nov 16, 2016

Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules

Nov 16, 2016

Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

Nov 4, 2016

Lycera Announces Publication of Immuno-Oncology Research, Demonstrating Differentiated Mechanism of RORgamma Agonists

Oct 19, 2016

Kineta CEO Unveils Its Immuno-oncology Program at the BIO Investor Forum

Oct 10, 2016

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m

Oct 10, 2016

Crescendo Biologics and Takeda Enter Collaboration for Humabody-based Therapeutics Worth up to $790m

Sep 7, 2016

Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer

Jun 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

May 20, 2016

Checkmate Pharmaceuticals Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer and Announces Dosing of First Patient in Immuno-Oncology Phase 1b Trial with CMP-001, a TLR9 Agonist

May 19, 2016

Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2α Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting

May 9, 2016

PureTech Teams with Siddhartha Mukherjee to Launch Vor BioPharma to Advance Novel Targeting Platform to Expand Applicability of CAR T-Cell Immunotherapies in Immuno-Oncology

May 5, 2016

FLX Bio Completes Leadership Team in Immuno-Oncology Drug Discovery

Apr 19, 2016

Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Apr 13, 2016

Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences

Feb 25, 2016

Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology

Feb 8, 2016

FLX Bio Hires Senior Leaders in Immuno-Oncology Drug Discovery

Jan 11, 2016

F-star Enters Into Collaborative Discovery & Development Agreement With AbbVie for Bispecific Antibodies in Immuno-oncology

Jan 7, 2016

Kymab and MD Anderson Announce Strategic Partnership in Immuno-Oncology Research & Development

Jan 7, 2016

OncoResponse and Oregon Health and Science University Collaborate to Identify Novel Immuno-Oncology Targets

Jan 4, 2016

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

Nov 6, 2015

Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting

Nov 3, 2015

Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting

Oct 1, 2015

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Aug 12, 2015

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment for Development of Novel Immuno-Oncology Product Platform

Jul 28, 2015

Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

Jul 28, 2015

DGAP-News: R-Biopharm and Apogenix Enter Cooperation to Develop Companion Diagnostic Tests for Apogenix' Immuno-Oncology Candidate APG101

Jul 15, 2015

Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China

Jun 16, 2015

Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M

May 6, 2015

Apexigen Selected to Present at Cavendish Global Health Impact Forum

Apr 21, 2015

Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics

Apr 21, 2015

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics